Adma Biologics (ADMA) ended the recent trading session at $15.30, demonstrating a -5.03% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.47%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq added 0.94%.
The infectious disease drug developer's stock has dropped by 5.18% in the past month, falling short of the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release. In that report, analysts expect Adma Biologics to post earnings of $0.16 per share. This would mark year-over-year growth of 6.67%. Meanwhile, our latest consensus estimate is calling for revenue of $130.1 million, up 8.56% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.57 per share and a revenue of $506.7 million, representing changes of +16.33% and +18.82%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Adma Biologics is presently being traded at a Forward P/E ratio of 28.26. This represents a premium compared to its industry average Forward P/E of 19.79.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
